Senior district sales manager
Lundbeck
Total years of experience :23 years, 8 Months
Leading the growth over the last three year in the field of CNS: 46% growth in the value over the last 3 years, increasing the portfolio value from 14.6 M SAR to 21.70 M SAR.
Improving the market shares of Ebixa from 53% into 58% within the last 3 years
Improving the market shares of Cipralex from 18% into 25% within the last 3 years
Evolve market segmentation & penetration strategies for launched Cipralex and Ebixa to reach to be market leader in the eastern area for the first time since the launch of both drugs.
Responsible to achieve market leadership for Cipralex (Antidepressant) for the first time after being launched since seven years in Riyadh and Eastern area.
Strategizing long term business directions through planning, manpower planning for maximum profitability in line with corporate strategies & goals.
Maintain the market leadership of Ebixa (Antidementia).
Succeeded to develop a second line manager.
Establish & maintain robust relationships with the Key opinion leaders within the territory.
Lead & monitor the performance of team to ensure efficiency in operations and meeting of individual & group targets.
Skilled in optimizing teams dynamics, uniting diverse agendas to a common goal, and harnessing strategic and operational drivers to deliver results.
Coaching with regular feedback and establish a developmental plan for each product specialist
Assign targets, goals, responsibilities and ensure the right performance with optimizing the KPIs within the available resources to ensure achieving the required results.
Conduct weekly meetings for setting up objectives & designing or streamlining processes to ensure smooth functioning of operations.
Identified, recruited, develop and nurtured strong Sales Team.
Participating in SPEED project by leading a group of employees for continuous development
District sales manager Mar 2010 - Present
Lundbeck Central and Eastern area of Saudi Arabia
• Achieving market leadership for Cipralex (Antidepressant) for the first time after being launched since seven years in Riyadh and Eastern area.
• Maintaining the market leadership of Ebixa (Antidementia)
• Achieving market leadership of Cipralex and Ebixa in the eastern area for the first time since the launch of both drugs.
• Establishing and monitoring the developmental plan for my team.
• Succeeded to develop a second line manager.
• Establishing robust relationships with the Key opinion leaders within the territory.
Institution Product specialist 2003 - 2010
Lundbeck Western area of Saudi Arabia
• Re launching Lundbeck Saudi after 2003 changes and establishes a team dedicated for institutions.
• Successful Cipralex launching in the institutions of the whole Western area (Saudi airlines medical services, King Fahd Military H, King Faisal Specialist H, Al Hada Military H, Tabuk Military H, Royal commission H Yanbo, and MOH of Jeddah)
• Saudi airlines medical services: replacing Cipram with Cipralex after 2 month from the launch and changing Cipralex from the 3rd place (12% market share) after Seroxate and Prozac by the end of 2004 into the first place (33% market share) by the end of 2005.
• King Fahd Military H: replacing Cipram with Cipralex after 1 month from the Launch and getting Cipralex market leader there.
• Al Hada Military H: Replacing Cipram with Cipralex on 2005 and getting it number one market share with 65% by the end of 2007.
• Tabuk Military H: Replacing Cipram with Cipralex on 2005.
Medical representative June 2000 - Dec 2002
Wyeth Port Said, Damietta, Arish
• Launching Tazocin, Effexor by the year 2000.
• Re launching Oscal after the local manufacturing.
• 1st introduction of Tazocin to the MOH all over Egypt 2000.
• Introduction of Tazocin to all Ministry of health hospitals of Port Said.
• Achievement for year 2000 is 122%
• Achievement for the year 2001 is 103%
• Achievement for the year 2002 is 101%
• Introduction of Tazocin on the formulary of Damietta oncology centre.
• Introduction of Tazocin into the formulary of Al Zarka general H.
Jan 2000 - June 2000 Medical representative
Bristol Myers Squibb Port Said
• Introduction of Amikin into Omar Ibn El Khatab H
• Bachelor of veterinary medicine, Good 1998 Suez Canal University Ismailia